univercellstech.comCrawled Nov 15, 2026
The chained, intensified, and low-footprint scale-X carbo system is upgraded with a new version offering improved functionalities that address the need for increased connectivity, data accessibility, automation, and sustained batch safety.
Univercells, now Univercells Technologies commercially launched its proprietary NevoLine bioproduction system for vaccines.
The scale-X carbo bioreactor offers a new standard in upstream performance, with the new design and functional improvements that simplify bioprocessing and secure batch safety
Launched in April 2019, The scale-X carbo is an intermediate scale system designed for rapid process development and GMP manufacturing
The NevoLine platform enables cost-effective manufacturing by supporting high cell densities, thereby reducing the cost per dose, says CTO of Exothera.
The scale-X nexo accelerated and facilitated the CER's process development journey, with reduced COGs due to its small surface and volume.
The Gene Therapy Vector Facility at King’s College London announced the addition of the Univercells Technologies’ scale-X carbo bioreactor to its GMP manufacturing portfolio
Univercells Technologies inaugurated a new facility in Nivelles, Belgium, for technology development and production.
Bench-scale automated cell culture system featuring the scale-X single-use fixed-bed bioreactor offering 10 to 30 m² growth surface.
Keep up to date
Univercells Technologies supports career growth for employees.
Anuv Ratan works in the health care industry team at KKR, with investments including Gamma Biosciences.
Julie heads Quality and Validation at Univercells Technologies, ensuring high-quality product delivery.
Kugan has played a significant role in KKR’s investments in LGC Group, Walgreens Boots Alliance, Gamma Biosciences, Alvogen and Galenica
Matthew serves as President at Gamma Biosciences, managing the company’s portfolio and investments.
Univercells Technologies offers biomanufacturing solutions for cost-effective viral production from research to scale-up.
Univercells Technologies was launched in May 2020 to focus on the development and commercialization of the technology portfolio initially developed by Univercells, including the scale-X single-use bioreactor and the NevoLine biomanufacturing platform.
Univercells Technologies holds patents worldwide for its technologies and products.
Univercells Technologies develops next-generation bioprocess technologies using process intensification and automation.